substances
Is kratom addictive
A clinical and analytical reference on kratom pharmacology, FDA and CDC surveillance posture, dependence and withdrawal characterization, and why standard opiate immunoassays do not detect mitragynine alkaloids — written for clinical, MAT, and program-administrator buyers.
·13 min read
Quick answer
Kratom (Mitragyna speciosa) contains alkaloids — principally mitragynine and 7-hydroxymitragynine — that act as partial agonists at the mu-opioid receptor while producing dose-dependent effects that shift from stimulant-like at lower exposures to opioid-like at higher exposures. FDA has issued import alerts and warning letters citing safety concerns, and CDC reports have documented kratom-involved deaths, typically in polysubstance contexts. Clinical literature describes a dependence and withdrawal syndrome consistent with opioid-class action. The analytical operational fact is that mitragynine alkaloids are structurally unrelated to morphine and do not cross-react with standard opiate immunoassays; programs requiring kratom coverage need a dedicated mitragynine immunoassay or LC-MS/MS confirmation panel. This is clinical reference, not medical or harm-reduction guidance.
Mitragynine and 7-hydroxymitragynine pharmacology
Kratom is derived from the leaves of Mitragyna speciosa, a tropical evergreen native to Southeast Asia. The plant contains a large family of indole alkaloids, of which mitragynine is the most abundant and 7-hydroxymitragynine the most pharmacologically potent. NIDA and NIH-affiliated literature describe these compounds as partial agonists at the mu-opioid receptor with additional activity at delta and kappa opioid receptors and at non-opioid targets including alpha-2 adrenergic and serotonergic receptors.
The clinical phenotype of kratom exposure is dose-dependent and biphasic. At lower exposures, kratom produces predominantly stimulant-like effects — increased alertness, sociability, and reduced fatigue — likely mediated through the combination of partial mu-opioid agonism and adrenergic activity. At higher exposures, the opioid-like effects predominate, including sedation, analgesia, and the respiratory-depression profile associated with mu-agonist activity. The dose-response transition explains why kratom users may describe their use pattern in stimulant terms while exhibiting clinical features consistent with opioid exposure.
7-hydroxymitragynine is a minor alkaloid by abundance but is approximately 10 to 20 times more potent than mitragynine at the mu receptor and may also be formed in vivo through hepatic metabolism of mitragynine. The functional pharmacology of a kratom exposure therefore reflects the combined activity of the parent mitragynine and the more potent 7-hydroxymitragynine metabolite, with the relative contribution varying by product source, preparation method, and individual metabolism.
FDA regulatory posture and import alerts
FDA has issued multiple import alerts citing kratom as an unapproved new drug and has detained kratom shipments at the border under those alerts. The agency has also issued warning letters to companies marketing kratom products with disease-treatment claims, citing the New Drug Application requirements that apply to any product marketed for prevention or treatment of disease. FDA has not approved kratom or any kratom-derived product for any medical indication.
FDA public communications have emphasized safety concerns including the potential for opioid-like effects, withdrawal syndromes, and adverse events documented in spontaneous-reporting and case-series literature. The agency has cautioned that consumers cannot reliably assess product composition because kratom products are not subject to FDA-approved manufacturing controls; alkaloid content varies substantially between products and between batches of the same product, and contamination with heavy metals and pathogenic bacteria has been documented in some sampled products.
DEA has not scheduled kratom under the Controlled Substances Act. The agency announced an intent to schedule mitragynine and 7-hydroxymitragynine in 2016 but withdrew the proposed scheduling in response to public comment and congressional inquiry, and the compounds have remained federally unscheduled since. State-level scheduling varies — some states have placed kratom on their controlled-substances schedules, others have enacted age-restricted-sale and labeling statutes, and most states have no kratom-specific regulation.
CDC reports on kratom-involved deaths
CDC has published case-series and surveillance reports describing kratom-involved deaths drawn from state-level mortality data and the State Unintentional Drug Overdose Reporting System (SUDORS). The published series consistently describe kratom-involved deaths as predominantly polysubstance events, with kratom typically detected alongside fentanyl, other opioids, benzodiazepines, or stimulants. The clinical narrative is generally consistent with a contributing rather than sole-cause role for kratom in most reported deaths.
A smaller subset of reported cases describes deaths in which kratom alkaloids were the only substances detected by post-mortem toxicology, raising the possibility of fatal opioid-class toxicity attributable to kratom alone in some exposures. The methodological challenges of post-mortem toxicology in kratom-involved cases include uncertain reference ranges for fatal mitragynine concentrations, variability in product composition, and the rarity of antemortem testing for direct comparison.
The operational implication for clinical and harm-reduction programs is that kratom exposure should be considered alongside other opioid-class exposures in differential diagnosis of altered mental status, respiratory depression, or overdose presentations — particularly when the donor reports stimulant or supplement use rather than opioid use. Programs serving populations with documented kratom prevalence should ensure that their analytical workflow can identify mitragynine when clinically relevant.
Dependence and withdrawal characterization
Clinical literature describes a kratom dependence and withdrawal syndrome consistent with mu-opioid-class pharmacology. Dependence is characterized by tolerance to subjective effects with continued use, escalation of dose or frequency, and difficulty discontinuing use despite adverse consequences. The clinical picture overlaps substantially with opioid use disorder as defined in DSM-5 criteria, although kratom is not specifically named in the criteria.
Withdrawal phenomenology described in case reports and case series includes classic opioid-withdrawal features: anxiety, irritability, muscle aches, gastrointestinal symptoms, autonomic instability, insomnia, and craving. Onset is typically within 12 to 24 hours of last use and duration is generally several days, with protracted symptoms in some cases. The severity reported across case series varies; some patients report withdrawal severity comparable to short-acting opioid withdrawal, while others report milder symptoms more consistent with caffeine-class withdrawal.
Treatment of kratom withdrawal in clinical settings has used the same medication categories applied to other opioid-class withdrawal — buprenorphine for symptomatic relief and transition to longer-term medications for opioid use disorder when clinically appropriate, alpha-2 adrenergic agonists (clonidine, lofexidine) for adjunctive autonomic management, and supportive care. ASAM and SAMHSA guidance on opioid use disorder treatment broadly applies, with the caveat that kratom is not specifically addressed in the regulatory frameworks governing MOUD prescribing. Clinicians should consult current addiction-medicine specialty resources for patient-specific decisions.
Why standard opiate immunoassays do not detect kratom
Mitragynine and 7-hydroxymitragynine are indole alkaloids structurally unrelated to morphine and codeine. Standard opiate immunoassays — calibrated to morphine and engineered for cross-reactivity with the morphine-related compound family (heroin metabolite 6-acetylmorphine, hydromorphone, and to varying degrees hydrocodone and oxymorphone) — produce no meaningful cross-reactivity to kratom alkaloids at any clinically relevant concentration. A urine specimen from a daily kratom user will produce a negative result on a SAMHSA opiate immunoassay regardless of mitragynine concentration.
The same is true of fentanyl-specific immunoassays. Although fentanyl is also a synthetic compound structurally distinct from morphine, fentanyl immunoassays are calibrated specifically to fentanyl and do not cross-react to mitragynine or 7-hydroxymitragynine. A program that wants kratom coverage cannot achieve it by adding fentanyl coverage; the two require separate analytical pathways.
Dedicated mitragynine immunoassays are now commercially available in point-of-care and laboratory formats, typically with cutoffs in the 100 to 300 ng/mL range in urine. LC-MS/MS confirmation panels target both mitragynine and 7-hydroxymitragynine, with quantitative reporting against calibrated standards. Reference laboratories serving addiction-medicine and clinical-toxicology programs increasingly offer kratom-specific confirmation as part of expanded synthetic-opioid panels.
| Analytical method | Targets | Typical cutoff | Operational role |
|---|---|---|---|
| SAMHSA-5 opiate immunoassay | Morphine, codeine, heroin metabolites | 2000 ng/mL or 300 ng/mL | Does NOT detect kratom alkaloids |
| Fentanyl-specific immunoassay | Fentanyl (limited analog cross-reactivity) | 1 ng/mL | Does NOT detect kratom alkaloids |
| Mitragynine immunoassay (POC or lab) | Mitragynine (variable 7-OH cross-reactivity) | 100-300 ng/mL | Screening for kratom exposure |
| LC-MS/MS kratom panel | Mitragynine + 7-hydroxymitragynine | 10-50 ng/mL (lab-dependent) | Confirmation, quantitation, defensible reporting |
Clinical and MAT screening relevance
Programs delivering medications for opioid use disorder (MOUD) — buprenorphine, methadone, and extended-release naltrexone — have a clinical interest in identifying kratom exposure in their patient populations. Kratoms partial mu-opioid agonism can complicate buprenorphine induction, MOUD adherence assessment, and treatment-response evaluation in ways analogous to other opioid-class exposures. A patient stable on MOUD who is using kratom intermittently presents a different clinical picture than a patient with no opioid-class exposure beyond their prescribed medication, and treatment-program response should be calibrated to the actual exposure pattern rather than to the patient-reported pattern alone.
For corrections and re-entry programs serving formerly incarcerated populations, kratom is among the substances that may be encountered post-release and is not detected by standard screening panels. Programs operating in regions with documented kratom prevalence — primarily Southeast Asian diaspora communities and broader populations with significant kratom-product retail availability — should consider including kratom coverage in their screening panel where clinically relevant.
For workplace testing, kratom is generally not included in standard panels and is not subject to federal mandate inclusion. Employers with safety-sensitive populations in regions of documented kratom prevalence may elect to add kratom coverage based on operational risk analysis and counsel-driven policy review. The analytical workflow, MRO defenses, and documentation requirements parallel those for other expanded-panel analytes; kratom is not federally scheduled, which means MRO handling of confirmed kratom-positive results does not follow the standardized federal pathway applicable to scheduled controlled substances.
Panel selection and documentation considerations
Programs evaluating kratom panel inclusion should weigh several factors. Local prevalence is the primary driver — kratom retail availability and documented community use vary substantially by region, and panel additions should be calibrated to actual operational need rather than to general national trends. Clinical context is the second factor — MAT, addiction-medicine, and clinical-toxicology programs have a stronger clinical rationale for kratom coverage than do general pre-employment or random workplace programs.
Operational complexity is the third factor. Adding kratom to a panel requires both the analytical capability (point-of-care immunoassay or laboratory confirmation) and the corresponding policy infrastructure (MRO protocol, donor explanation handling, documentation discipline). Programs that add a kratom analyte without updating policy and MRO instructions can produce results that are technically valid but operationally difficult to act on.
Documentation should reflect the same chain-of-custody and procedural discipline applied to other analytes. Collection records, chain-of-custody forms, laboratory reports, MRO review, donor explanations, and any adverse-action decisions should be retained per the records-retention requirements applicable to the program type. For non-federal programs, retention periods are set by counsel based on jurisdiction-specific statutes and any applicable contract or collective-bargaining obligations.
Adulterant landscape and product-composition variability
FDA sampling of consumer kratom products has documented substantial variability in alkaloid content across products and across batches of the same product, as well as contamination findings including heavy metals (lead, nickel) and pathogenic bacteria (Salmonella species) in some sampled lots. The agency has issued recall and warning communications related to specific contamination findings. The operational implication for clinical and surveillance programs is that a donor reporting consistent kratom-product use may have substantial variability in actual mitragynine and 7-hydroxymitragynine exposure across time, independent of any change in self-reported use pattern.
Some products marketed as kratom or kratom-containing have been found to contain synthetic 7-hydroxymitragynine-enriched preparations or co-formulated synthetic-opioid analogs. The synthetic-opioid co-formulation phenomenon is the most clinically concerning because it can produce respiratory-depression risk profiles inconsistent with the conventional kratom pharmacology a clinician or donor might anticipate. Reference-laboratory expanded synthetic-opioid panels can identify these co-formulations when clinically relevant.
For programs operating in jurisdictions with state-level kratom regulation — age-restricted sale statutes, labeling requirements, or scheduling actions — the regulatory framework may itself shift the product landscape in the program operating area. State public-health and consumer-protection bulletins provide the most current jurisdiction-specific information; programs should not rely on national-level summaries for jurisdiction-specific compliance and policy decisions.
Detection windows and matrix selection
Urinary detection windows for mitragynine and 7-hydroxymitragynine vary with exposure pattern, individual metabolism, and laboratory cutoff. After a single moderate exposure, parent mitragynine may be detectable for approximately 24 to 72 hours and 7-hydroxymitragynine for a shorter period reflecting its lower concentration. After sustained daily-use exposure patterns, urinary mitragynine can be detectable for substantially longer — generally a week or more, with extended detection in patterns of heavy chronic exposure.
Oral-fluid detection windows are shorter than urinary windows, reflecting matrix-specific kinetics. Oral-fluid mitragynine assays are less widely deployed than urinary assays at present, and programs interested in oral-fluid kratom coverage should consult their device manufacturer and reference laboratory about current analytical availability. Hair-matrix kratom testing is technically feasible but operationally uncommon in current programs.
Matrix selection should be calibrated to the operational question. For MAT monitoring of sustained kratom exposure pattern, urinary screening with laboratory confirmation provides the most informative result. For workplace post-accident or reasonable-suspicion testing in regions where kratom is operationally relevant, the shorter oral-fluid window may better address the recent-use question that drives the testing event. As with other expanded-panel analytes, matrix selection should be deliberate and documented in written policy rather than defaulted across all testing scenarios.
Key takeaways
- ✓Mitragynine and 7-hydroxymitragynine are partial mu-opioid agonists with dose-dependent effects that shift from stimulant-like at lower exposures to opioid-like at higher exposures.
- ✓FDA has issued import alerts and warning letters citing kratom safety concerns; the agency has not approved kratom for any medical indication. DEA has not federally scheduled kratom; state regulation varies.
- ✓CDC surveillance reports describe kratom-involved deaths as predominantly polysubstance events, with a smaller subset of mitragynine-only post-mortem detections raising questions about kratom-attributable fatal toxicity.
- ✓Clinical literature describes a dependence and withdrawal syndrome consistent with mu-opioid-class pharmacology, typically managed with the same medication categories applied to other opioid-class withdrawal.
- ✓Standard opiate immunoassays and fentanyl-specific immunoassays do not detect mitragynine alkaloids; programs requiring kratom coverage need a dedicated mitragynine immunoassay or LC-MS/MS confirmation panel.
- ✓Panel-inclusion decisions should reflect local prevalence, clinical context, and operational complexity; MAT and addiction-medicine programs have the strongest clinical rationale for kratom coverage.
Sources
- FDA·FDA and Kratom
- NIDA·Kratom DrugFacts
- CDC·Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected
- SAMHSA·Medications for Substance Use Disorders
Information in this article is provided for educational reference and is not medical, legal, or clinical advice. Consult qualified professionals for guidance specific to your program.